Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report

T Pressler; C Bohmova; S Conway; S Dumcius; L Hjelte; N Høiby; H Kollberg; B Tümmler; V Vavrova

doi:10.1016/S1569-1993(11)60011-8

Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report

T Pressler, C Bohmova, S Conway, S Dumcius, L Hjelte, N Høiby, H Kollberg, B Tümmler, V Vavrova

Department of Immunology and Microbiology

99 Citations (Scopus)

Abstract

Chronic pulmonary infection with P. aeruginosa develops in most patients with cystic fibrosis (CF); by adulthood 80% of patients are infected and chronic P. aeruginosa infection is the primary cause of increased morbidity and mortality in CF. Chronic infection is preceded by an intermittent stage of infection. The initial stage is characteristically followed by the gradual emergence of mucoid variants of the colonizing strains and a rise in anti-Pseudomonas antibodies. In addition to optimizing existing therapeutic strategies, effective new agents need to be identified. Studies in patients with CF are particularly challenging: the progressive nature of the disease and the wide variation in severity influence considerably the outcome of drug testing. A validated, universally accepted, and clinically useful classification of patients infected with P. aeruginosa, particularly those chronically infected, is needed that can be used as both a criterion for patient selection for clinical trials and as a study endpoint.

Original language	English
Journal	Journal of Cystic Fibrosis
Volume	10 Suppl 2
Pages (from-to)	S75-8
ISSN	1569-1993
DOIs	https://doi.org/10.1016/S1569-1993(11)60011-8 https://doi.org/10.1016/S1569-1993(11)60011-8
Publication status	Published - Jul 2011

Access to Document

Cite this

@article{294d3a971ffe42129f2edafb205c42c8,

title = "Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report",

abstract = "Chronic pulmonary infection with P. aeruginosa develops in most patients with cystic fibrosis (CF); by adulthood 80% of patients are infected and chronic P. aeruginosa infection is the primary cause of increased morbidity and mortality in CF. Chronic infection is preceded by an intermittent stage of infection. The initial stage is characteristically followed by the gradual emergence of mucoid variants of the colonizing strains and a rise in anti-Pseudomonas antibodies. In addition to optimizing existing therapeutic strategies, effective new agents need to be identified. Studies in patients with CF are particularly challenging: the progressive nature of the disease and the wide variation in severity influence considerably the outcome of drug testing. A validated, universally accepted, and clinically useful classification of patients infected with P. aeruginosa, particularly those chronically infected, is needed that can be used as both a criterion for patient selection for clinical trials and as a study endpoint.",

author = "T Pressler and C Bohmova and S Conway and S Dumcius and L Hjelte and N H{\o}iby and H Kollberg and B T{\"u}mmler and V Vavrova",

year = "2011",

month = jul,

doi = "10.1016/S1569-1993(11)60011-8",

language = "English",

volume = "10 Suppl 2",

pages = "S75--8",

journal = "Journal of Cystic Fibrosis",

issn = "1569-1993",

publisher = "Elsevier",

}

TY - JOUR

T1 - Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report

AU - Pressler, T

AU - Bohmova, C

AU - Conway, S

AU - Dumcius, S

AU - Hjelte, L

AU - Høiby, N

AU - Kollberg, H

AU - Tümmler, B

AU - Vavrova, V

PY - 2011/7

Y1 - 2011/7

N2 - Chronic pulmonary infection with P. aeruginosa develops in most patients with cystic fibrosis (CF); by adulthood 80% of patients are infected and chronic P. aeruginosa infection is the primary cause of increased morbidity and mortality in CF. Chronic infection is preceded by an intermittent stage of infection. The initial stage is characteristically followed by the gradual emergence of mucoid variants of the colonizing strains and a rise in anti-Pseudomonas antibodies. In addition to optimizing existing therapeutic strategies, effective new agents need to be identified. Studies in patients with CF are particularly challenging: the progressive nature of the disease and the wide variation in severity influence considerably the outcome of drug testing. A validated, universally accepted, and clinically useful classification of patients infected with P. aeruginosa, particularly those chronically infected, is needed that can be used as both a criterion for patient selection for clinical trials and as a study endpoint.

AB - Chronic pulmonary infection with P. aeruginosa develops in most patients with cystic fibrosis (CF); by adulthood 80% of patients are infected and chronic P. aeruginosa infection is the primary cause of increased morbidity and mortality in CF. Chronic infection is preceded by an intermittent stage of infection. The initial stage is characteristically followed by the gradual emergence of mucoid variants of the colonizing strains and a rise in anti-Pseudomonas antibodies. In addition to optimizing existing therapeutic strategies, effective new agents need to be identified. Studies in patients with CF are particularly challenging: the progressive nature of the disease and the wide variation in severity influence considerably the outcome of drug testing. A validated, universally accepted, and clinically useful classification of patients infected with P. aeruginosa, particularly those chronically infected, is needed that can be used as both a criterion for patient selection for clinical trials and as a study endpoint.

U2 - 10.1016/S1569-1993(11)60011-8

DO - 10.1016/S1569-1993(11)60011-8

M3 - Journal article

SN - 1569-1993

VL - 10 Suppl 2

SP - S75-8

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

ER -

Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report

Abstract

Access to Document

Fingerprint

Cite this